Previsão
O preço-alvo médio dos analistas é € 15,47 (+344,54%). A mediana é € 18,20 (+422,99%).
| Comprar |
8 |
| Manter |
2 |
| Vender |
0 |
Discussões na comunidade
Ainda não há nenhuma discussão sobre este ativo.
Iniciar discussãoNotícias Ir para o feed de notícias
Nuvation Bio reports strong launch of IBTROZI and positive Safusidenib data
At the Cantor Fitzgerald Healthcare Conference, Nuvation Bio said IBTROZI reached roughly 20% of the theoretical ROS1 market in its first year and uptake in first-line therapy continues to grow. The company holds $700 million in cash and considers itself well positioned financially to fund commercialization and its pipeline. Safusidenib showed a 79% non‑progression rate and a 52% response rate at 3 years, and multiple studies are planned through 2029. Management forecasts a peak sales potential for IBTROZI of $4–5 billion at full market penetration, while warning of development risks and emphasizing disciplined capital deployment. » Mais em de.investing.com
Nuvation Bio receives FDA fast-track for safusidenib and Cantor-Fitzgerald starts coverage with 12 USD target
The FDA granted safusidenib fast-track status for the treatment of IDH1‑mutated gliomas based on phase 2 data (confirmed objective response rate 51.9%, median progression‑free survival not yet reached, 36‑month PFS 79.1%). The designation enables more intensive interaction with the agency and a possible rolling review, reducing regulatory risk while the phase 3 SIGMA study continues to enroll. Cantor Fitzgerald initiated coverage with an “Overweight” rating and set a price target of 12 USD, with revenue forecasts of roughly 965 million USD for IBTROZI and about 1.9 billion USD for safusidenib. The news pushed the stock higher intraday (rise to 7.02 USD). » Mais em de.investing.com
Nuvation Bio receives FDA fast-track for safusidenib in IDH1 gliomas
The FDA has granted fast-track designation to safusidenib, an oral investigational candidate from Nuvation Bio for the treatment of IDH1‑mutant gliomas. The decision is based on phase‑2 data (J201) showing a confirmed objective response rate of 51.9% and a 36‑month progression‑free survival of 79.1%; median PFS has not yet been reached. Nuvation is currently recruiting for the registrational phase‑3 SIGMA trial, which will evaluate safusidenib as maintenance therapy versus placebo after standard treatment in IDH1‑mutant astrocytomas with high‑risk features (about 300 patients). Safusidenib is a selective inhibitor of mutant IDH1 designed to penetrate the blood–brain barrier; no new long‑term safety signals have been reported. » Mais em de.investing.com
Nuvation Bio receives Overweight from JPMorgan after robust second quarter
Nuvation Bio reports a solid second quarter and cash of $661 million. JPMorgan initiated coverage with an "Overweight" rating and a $13 price target, supported by expected first-line uptake. The bank sees additional revenue potential in prevalence-driven gene sequencing and in the pipeline around Safusidenib; the company remains focused on targeted cancer therapies and has a strengthened capital base. » Mais em finanzen.net
Nuvation Bio reports Q2 revenue growth for IBTROZI and expands safusidenib trials
Nuvation Bio posted Q2 total revenue of $31.7 million with U.S. IBTROZI product sales of $23.2 million, a 25% sequential increase as use shifts toward first-line ROS1 patients. Management highlighted stronger first-line uptake and longer treatment durations, supported by favorable TRUST-I and patient-reported outcomes. The company expanded safusidenib development with a Phase III trial in newly diagnosed Grade 2 IDH1-mutant glioma and a Phase II study for post-vorasidenib patients, citing durable Phase II results. Nuvation ended June with $661 million in cash and securities and raised about $279.1 million via convertible notes, which management says supports operations through profitability and the anticipated safusidenib launch. » Mais em finance.yahoo.com
Dados financeiros
No último trimestre, Nuvation Bio Inc Ordinary Shares - Class A registou receitas de € 39,68 mi e um ganho líquido de -€ 36,99 mi
| (EUR) | setembro de 2026 | YoY |
|---|---|---|
| Receitas | 39,68 mi | 254,97% |
| Ganho bruto | 29,15 mi | 250,14% |
| Ganho líquido | -36,99 mi | 22,19% |
| EBITDA | -31,08 mi | 33,39% |
Dados fundamentais
| Métrica | Valor |
|---|---|
Capitalização bolsista | € 1,21 bi |
Número de ações | 352,02 mi |
Máximo/mínimo de 52 semanas | € 8,87 - € 3,43 |
| Dividendos | Não |
Beta | 1,73 |
PER (PE Ratio) | -9,58 |
PEG (PEG Ratio) | -0,20 |
P/VC (PB Ratio) | 5,83 |
P/V (PS Ratio) | 6,60 |
Perfil da empresa
A Nuvation Bio Inc., uma empresa biofarmacêutica em fase clínica, dedica-se ao desenvolvimento de candidatos terapêuticos para oncologia. O principal candidato a produto da empresa é o NUV-422, um inibidor de moléculas pequenas que tem como alvo as cinase dependentes de ciclina (CDK) 2, CDK4 e CDK6. A empresa desenvolve também o NUV-868, um inibidor BET oral seletivo de moléculas pequenas que regula epigeneticamente proteínas que controlam o crescimento e a diferenciação tumoral; o NUV-569, um inibidor oral seletivo de moléculas pequenas diferenciado da cinase Wee1 para a reparação de danos no ADN; o NUV-1182, um inibidor do recetor de adenosina; e uma plataforma de conjugados fármaco-fármaco (DDC) que se concentra em direcionar um inibidor da poli(ADP-ribose) polimerase (PARP) para as ogivas anticancerígenas de fármacos existentes, bem como um inibidor da PARP para tratar o cancro da mama ER+ e o cancro do ovário. A empresa era anteriormente conhecida como RePharmation Inc. e mudou o nome para Nuvation Bio Inc. em abril de 2019. A Nuvation Bio Inc. foi fundada em 2018 e tem sede em Nova Iorque, Nova Iorque.
| Nome | Nuvation Bio Inc Ordinary Shares - Class A |
| CEO | David T. Hung |
| Sede | New York City,
ny EUA |
| Site | |
| Setor | Materiais básicos |
| Indústria | Produtos químicos |
| Entrada em bolsa | 26/08/2020 |
| Colaboradores | 310 |
Análise aprofundada
Símbolos de ticker
| Bolsa | Símbolo |
|---|---|
NYSE | NUVB |